To include your compound in the COVID-19 Resource Center, submit it here.

CXA-201: Phase III started

Cubist began a double-blind, international Phase III trial to compare 1,500 mg IV

Read the full 136 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE